Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Topical delgocitinib (JTE-052), a novel Janus kinase inhibitor, had been shown to be clinically effective in adults with atopic dermatitis (AD). However, the efficacy of topical delgocitinib in pediatric patients with AD remained unclear. OBJECTIVE: We sought to evaluate the efficacy and safety of delgocitinib ointment in pediatric patients with AD. METHODS: In this phase 2 clinical study (JapicCTI-173553) Japanese patients aged 2 through 15 years with AD were randomized in a 1:1:1 ratio to receive 0.25% or 0.5% delgocitinib ointment or vehicle ointment twice daily for 4 weeks. The primary efficacy end point was the percentage change from baseline in the modified Eczema Area and Severity Index score at the end of treatment (EOT). RESULTS: At EOT, modified Eczema Area and Severity Index scores in both delgocitinib groups were significantly reduced compared with that in the vehicle group. The least-squares mean percentage change from baseline was -54.2% in the 0.25% group and -61.8% in the 0.5% group versus -4.8% in the vehicle group (P < .001 for both comparisons). Similarly, all other efficacy parameters, including Investigator's Global Assessment and pruritus scores, in both delgocitinib groups were significantly improved compared with those in the vehicle group at EOT. Adverse events in both delgocitinib groups were mild in severity, and no serious adverse events were reported. CONCLUSIONS: Delgocitinib ointment improved clinical signs and symptoms in pediatric patients with AD and was well tolerated. These study results indicate that delgocitinib ointment can be a promising therapeutic option for pediatric patients with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationNew insights into atopic dermatitis
Leung, D. Y. M., Boguniewicz, M., Howell, M. D., Nomura, I., & Hamid, Q. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21060 · Cited by 1,435
Filaggrin Mutations Associated with Skin and Allergic Diseases
Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011040 · Cited by 1,217
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Self-citationThe atopic march and atopic multimorbidity: many trajectories, many pathways
Paller, A. S., Spergel, J. M., Mina-Osorio, P., & Irvine, A. D. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.006 · Cited by 464
Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases
Kubo, A., Nagao, K., & Amagai, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57416 · Cited by 378
Dupilumab: A review of its use in the treatment of atopic dermatitis
Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.022 · Cited by 343
Egawa, G., & Kabashima, K. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.002 · Cited by 265
Self-citation
Cited by
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
JAK inhibitors in the treatment of atopic dermatitis
Chovatiya, R., & Paller, A. S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.009 · Cited by 398
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
Huang, I.-H., Chung, W.-H., Wu, P.-C., & Chen, C.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1068260 · Cited by 329
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01291-2 · Cited by 126
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Légaré, S., Chagnon, M., Palijan, A., Kojok, K., & Bissonnette, R. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17743 · Cited by 6
Metadata
- Authors
- Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Oda, M., Kabashima, K., & Nagata, T.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 144
- Issue
- 6
- Pages
- 1575-1583
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2967103828
- Cited by
- 108
- References
- 16
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.